Gsa Capital Partners LLP Acelrx Pharmaceuticals Inc Transaction History

Gsa Capital Partners LLP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$0.49 - $1.02 $186,120 - $387,433	-379,837 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$0.93 - $1.51 $4,058 - $6,589	-4,364 Reduced 1.14%	379,837 $387,000
Q2 2021 Aug 05, 2021	BUY	$1.03 - $1.7 $203,981 - $336,668	198,040 Added 106.38%	384,201 $530,000
Q1 2021 May 10, 2021	SELL	$1.25 - $2.77 $22,086 - $48,943	-17,669 Reduced 8.67%	186,161 $316,000
Q4 2020 Feb 03, 2021	BUY	$1.18 - $1.98 $53,874 - $90,398	45,656 Added 28.86%	203,830 $253,000
Q3 2020 Nov 06, 2020	BUY	$1.01 - $1.81 $135,933 - $243,604	134,588 Added 570.63%	158,174 $225,000
Q2 2020 Aug 11, 2020	SELL	$1.03 - $1.69 $93,576 - $153,538	-90,851 Reduced 79.39%	23,586 $29,000
Q4 2019 Feb 12, 2020	BUY	$1.66 - $2.4 $189,965 - $274,648	114,437 New	114,437 $241,000
Q4 2018 Feb 12, 2019	SELL	$2.13 - $4.8 $255,936 - $576,758	-120,158 Closed	0 $0
Q3 2018 Nov 13, 2018	BUY	$2.6 - $4.6 $172,900 - $305,900	66,500 Added 123.93%	120,158 $463,000
Q1 2018 May 11, 2018	BUY	$1.7 - $2.35 $91,218 - $126,096	53,658 New	53,658 $113,000

Ticker ACRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 7,366,600
Market Cap $8.32M
Description
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed ...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.